Levels of total, apoptotic and necrotic cells death markers for diagnosis of advanced fibrosis (F≥3) in 143 alcoholic patients.

<p>The area under the ROC curves are shown for the performance of the total (CK18 total), apoptotic (CK18 fragment) and necrotic (CK18 total-fragment) cell death markers for predicting advanced fibrosis (F≥3).</p

Characteristics of Serum and Gene groups.

<p>Data are expressed as Median (25th, 75th percentile) or %. AST: aspartate amino-tranferase; ALT: alanine amino-transferase; γGT: Gamma Glutamyl Transpeptidase.</p

Correlation between hepatic TGFβ, TNFα and Fas-L gene expression and circulating levels of total, apoptotic and necrotic cell death markers in 24 alcoholic patients.

<p>The correlation between the expression levels of TGFβ, TNFα and Fas-L mRNA (ΔCt) and circulating levels of biomarkers was analyzed using the Spearman's rank correlation test.</p

Correlation between circulating levels of total, apoptotic and necrotic cell death markers and hepatic inflammation, Mallory-Denk bodies, ballooning and fibrosis in 143 alcoholic patients.

<p>Spearman's rank correlation test.</p

Total, apoptotic and necrotic cell death marker levels for prediction of severe fibrosis (F≥3) (n = 143).

<p>PPV: Positive Predictive value, NPV: Negative Predictive value; Prev: Prevalence.</p

Univariate analysis of the 143 alcoholic patients according to the severity of liver disease.

<p>Patients were classified as Fibrosis (F) <3 or ≥3. Quantitative results are expressed as means ± standard deviations. AST: aspartate amino-tranferase; ALT: alanine amino-transferase; γGT: Gamma Glutamyl Transpeptidase.</p

Elevated serum levels of total, apoptotic and necrotic cell death markers in patients with hepatic inflammation and advanced fibrosis.

<p>The serum of 143 alcoholic patients were used to evaluate the circulating levels of total CK18 (M65® ELISA) and the caspases-generated CK18 fragment (M30 Apoptosense® ELISA). Results were expressed as median (25^th, 75^th percentile) in function to: (A) hepatic inflammation (A1) and (B) advanced fibrosis (F3/4).</p

Characteristics of the Estimation, Second Gene and Validation groups.

<p>Data are expressed as Means ± SEM or N (%). AST: aspartate amino-tranferase; ALT: alanine amino-transferase; γGT: Gamma Glutamyl Transpeptidase.</p

Levels of serum OPN in patients with chronic viral hepatitis C.

<p>(<b>A</b>) The circulating levels of OPN were measured in the serum of 86 patients with chronic hepatitis C (25 F1, 34 F2, 19 F3, 8 F4) and analyzed according to the stage of fibrosis. Results were expressed as the median (25^th, 75^th percentile). The Kruskal-Wallis test was used to compare the 4 groups F1, F2, F3 and F4: <i>P</i><0.001. The Mann-Whitney test compared the two groups: &, <i>P</i>≤0.048, compared with F1; #, <i>P</i>≤0.026, compared with F2. Correlation between the serum OPN level with hepatic fibrosis was analyzed using the Spearman's rank correlation test. (<b>B</b>) The areas under the ROC curves are shown for the performance of serum OPN levels in estimating significant fibrosis (F≥2) or advanced fibrosis (F≥3) in this cohort.</p

Multivariate analysis of the Estimation group for the assessment of significant hepatic fibrosis.

<p>Patients were classified according to Fibrosis (F)<2 or ≥2. Multivariate analysis was realized using logistic regression.</p